Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-34907

ABSTRACT: Genetic and epigenetic determinants of neurogenesis and myogenesis [expression profiling]

OTHER RELATED OMICS DATASETS IN: PRJNA156259PRJNA156261PRJNA150167

PROVIDER: E-GEOD-34907 | ExpressionAtlas | 2015-09-22

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Similar Datasets

DNA mismatch repair (MMR) protein immunohistchemistry of hereditary non-polyposis colorectal cancer (HNPCC) related tumors and genetic analysis of MMR gene mutations.

Project description:Interventions: IHC of MMR proteins, genetic or epigenetic analyses of MMR genes Primary outcome(s): Screening of HNPCC related tumors by IHC for loss of MMR protein expression and observation of the clinical features assciated with MMR deficiency. Study Design: Single arm Non-randomized

| 2621222 | ecrin-mdr-crc

Mus musculus

Project description:Genetic and epigenetic determinants of neurogenesis and myogenesis [expression profiling]

| PRJNA156261 | ENA

BRD9 regulates leukemic cell survival via STAT5 pathway inhibition

Project description:Leukemia is characterized by genetic and epigenetic mutations resulting in selection of cancer stem cells, which are unable to differentiate. While genetic alterations are difficult to target, the epigenome is intrinsically dynamic and readily offers new therapeutic strategies. Thus, identifying cancer-specific context-dependent targets and unraveling their biological function may open up new therapeutic perspectives. Here, we identify bromodomain-containing protein 9 (BRD9) as a critical target required in acute myeloid leukemia (AML). We show that BRD9 is overexpressed in AML cells including ex vivo primary blasts compared to CD34+. By targeting BRD9 expression in AML, we observed an alteration in proliferation and survival, ultimately resulting in the induction of apoptosis. Intriguingly, genome-wide profiling revealed that BRD9 binds enhancer regions in a cell type-specific manner, regulating cell type-related processes. We unveil a novel BRD9-sustained STAT5 pathway activation via regulation of SOC3 expression levels. Our findings identify a previously undescribed BRD9-STAT5 axis as critical for leukemia maintenance, suggesting BRD9 as a potential therapeutic target.

2019-11-11 | PXD013245 | Pride

Defining the effects of genetic variation on a proteome-wide scale

Project description:Genetic variation governs protein expression through both transcriptional and post-transcriptional processes. To investigate this relationship, we combined a multiplexed, mass spectrometry-based method for protein quantification with an emerging mouse model harboring extensive genetic variation from 8 founder strains. We collected genome-wide mRNA and protein profiling measurements to link genetic variation to protein expression differences in livers from 192 diversity outcross mice. We observed nearly 3,700 protein-level quantitative trait loci (pQTL) with an equal proportion of proteins regulated directly by their cognate mRNA as uncoupled from their transcript. Our analysis reveals an extensive array of at least five models for genetic variant control of protein abundance including direct protein-to-protein associations that act to achieve stoichiometric balance of functionally related enzymes and subunits of multimeric complexes.

2017-11-08 | MSV000081696 | MassIVE

Genetic and epigenetic determinants of neurogenesis and myogenesis

Project description:This SuperSeries is composed of the following subset Series: GSE34906: Genetic and epigenetic determinants of neurogenesis and myogenesis [ChIP-seq] GSE34907: Genetic and epigenetic determinants of neurogenesis and myogenesis [expression profiling] Refer to individual Series

2012-03-26 | E-GEOD-34908 | biostudies-arrayexpress

An exploratory study to evaluate molecular predictive and/or prognostic factors of benefit from a randomized, phase III trial of sequential capecitabine/5FU plus bevacizumab (Cape/5FU-Bmab) to capecitabine/5FU plus oxaliplatin plus bevacizumab (CapeOX/mFOLOFX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer.

Project description:Primary outcome(s): Correlation between image evaluation/clinical data and molecular predictive and/or prognostic factors including genetic and epigenetic alterations derived from colorectal cancer tissues

| 2631489 | ecrin-mdr-crc

Project description:Genetic and Epigenetic Profiling of the Infertile Male

| PRJNA509073 | ENA

Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer

Project description:The goal of this laboratory research is to look for genetic and epigenetic markers that can predict which patients with stage III colorectal cancer will benefit from fluorouracil-based adjuvant chemotherapy.

| 2242379 | ecrin-mdr-crc

Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma

Project description:Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma

| PRJNA126443 | ENA

Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.

Project description:The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. The genome analysis needs systematic infra and database based on personal genetic information. Therefore, a big data of genome-clinical information is important. To determine the feasibility of the use of tumor’s molecular profiling and targeted therapies in the treatment of advanced cancer and to determine the clinical outcome(Response rate,PFS, duration of response and overall survival )of patients with advanced cancer, the investigators are going to take a tumor tissue of patients and process molecular profiling and receive molecular profile directed treatments.

| 2201468 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data